期刊
MUCOSAL IMMUNOLOGY
卷 13, 期 5, 页码 799-813出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/s41385-020-0293-7
关键词
-
类别
资金
- University of Liege (VIR-IMPRINT ARC)
- Fonds de la Recherche Scientifique - Fonds National Belge de la Recherche Scientifique F.R.S./FNRS [J007515F, T.0195.16]
- Institut MERIEUX
- EOS joint programme of F.R.S./FNRS [30981113]
- EOS joint programme of Fonds wetenschapellijk onderzoek - Vlaanderen - FWO [30981113]
- ERC Starting Grant (ERC-StG-2020 VIROME) [853608]
- European Research Council (ERC) [853608] Funding Source: European Research Council (ERC)
Human respiratory syncytial virus (RSV) is a pneumovirus that causes severe infections in infants worldwide. Despite intensive research, safe and effective vaccines against RSV have remained elusive. The main reason is that RSV infection of children previously immunized with formalin-inactivated-RSV vaccines has been associated with exacerbated pathology, a phenomenon called RSV vaccine-enhanced respiratory disease. In parallel, despite the high RSV prevalence, only a minor proportion of children develop severe diseases. Interestingly, variation in the immune responses against RSV or following RSV vaccination could be linked with differences of exposure to microbes during childhood. Gammaherpesviruses (gamma HVs), such as the Epstein-Barr virus, are persistent viruses that deeply influence the immune system of their host and could therefore affect the development of pneumovirus-induced immunopathologies for the long term. Here, we showed that a previous gamma HV infection protects against both pneumovirus vaccine-enhanced disease and pneumovirus primary infection and that CD8 T cells are essential for this protection. These observations shed a new light on the understanding of pneumovirus-induced diseases and open new perspectives for the development of vaccine strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据